

# **Hormone Refractory Prostate Cancer**

**Donald J. Tindall, Ph.D.**

**Mayo Clinic College of Medicine**

**Rochester, MN**







11. P. Red  
in 5% Acetic Acid

8200  
Fis  
20


last prot.  
Thurs 3/10

4


2X

700


# Regulation of AR Activity




# AR and Systemic Prostate Cancer Therapy





# PROSTATE CANCER AND ANDROGEN RECEPTOR








# Model of Prostate Cancer Progression




- ADI growth *in vivo* and *in vitro*
- AR positive
- AR dependent
- express PSA

# PSA mRNA Expression




## Key Findings





Dehm and Tindall, *JBC*, 2006



# Role of the AR NTD



# TAU5 Characterization



# Role of AR WHTLF and TAU5 on Chromatin




AR replacement plasmid feature

AR shRNA:	-	+
EGFP:	+	+


AR replacement plasmid feature

AR shRNA:	-	+	+	+	+
AR <sup>sr</sup> :	-	-	w.t.	ΔTAU5	AHTAA
EGFP:	+	+	+	+	+



C4-2, no androgens



# WHTLF Mediates TAU5 Activity





# WHTLF is an Autonomous Transactivation Domain





# Summary and Conclusions



## Acknowledgements

### Colleagues

Scott Dehm, Ph.D.  
Haojie Huang, Ph.D.  
Hannelore Heemers, Ph.D.  
Kaustubh Datta, Ph.D.  
Zheng Fu, Ph.D.  
Michael Muders, M.D., Ph.D.  
Heyu Zhang, M.D., Ph.D.  
Kristin Raclaw  
Diping Wang

### Technical Support

Kevin Regan  
Lucy Schmidt

### Funding

NCI  
NIDDK  
TJ Martell Foundation  
Charlotte Geyer Foundation  
NCIC/TFF

